Comparison of two high-throughput semiconductor chip sequencing platforms in noninvasive prenatal testing for Down syndrome in early pregnancy

BMC Medical Genomics

Volumn 9, Issue 1, 2016, Pages

  Kim, Sunshin ^a   Jung, Hee Jung ^b   Han, Sung Hee ^c   Lee, Seung Jae ^b   Kwon, Jeong Sub ^b   Kim, Min Gyun ^d   Chu, Hyungsik ^e   Chen, Hongliang ^f   Han, Kyudong ^g   Kwak, Hwanjong ^h   Park, Sunghoon ^h   Joo, Hee Jae ^h   Kim, Byung Chul ⁱ   Bhak, Jong ^a,i,j,k  

^a GenomeCare   (South Korea)

^b Mirae and Heemang Ob/Gyn Clinic   (South Korea)

^c Seoul Clinical Laboratories   (South Korea)

^d Namujungwon Maternity Hospital   (South Korea)

^e GN Maternity Hospital   (South Korea)

^f Xiamen Vangenes BioTech ^*  (China)

^g Dankook University   (South Korea)

^h Theragen ETEX Bio Institute   (South Korea)

ⁱ Ulsan National Institute of Science and Technology   (South Korea)

^j Geromics   (South Korea)

^k Personal Genomics Institute Genome Research Foundation   (South Korea)

more..

Author keywords

Circulating fetal DNA; Genome; Non invasive prenatal testing; Sequencing; Trisomy

Indexed keywords

ADULT; ALGORITHM; ANEUPLOIDY; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DOWN SYNDROME; FEMALE; FETUS DISEASE; FIRST TRIMESTER PREGNANCY; GESTATION PERIOD; HIGH RISK PREGNANCY; HIGH THROUGHPUT SEQUENCING; HUMAN; KARYOTYPING; KOREA; LAB ON A CHIP; NON INVASIVE MEASUREMENT; PREDICTIVE VALUE; PREGNANT WOMAN; PRENATAL SCREENING; PRIORITY JOURNAL; SEMICONDUCTOR; SENSITIVITY AND SPECIFICITY; TRISOMY 21; COMPARATIVE STUDY; DEVICES; EARLY DIAGNOSIS; GENETICS; PREGNANCY; PRENATAL DIAGNOSIS;

ADULT; DOWN SYNDROME; EARLY DIAGNOSIS; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; PREGNANCY; PRENATAL DIAGNOSIS; SEMICONDUCTORS;

EID: 85007587004     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/s12920-016-0182-9     Document Type: Article

References (36)

1. Morgan S, Delbarre A, Ward P. Impact of introducing a national policy for prenatal Down syndrome screening on the diagnostic invasive procedure rate in England. Ultrasound Obstet Gynecol. 2013;41(5):526-9.
2. ACOG Practice Bulletin No. 77. screening for fetal chromosomal abnormalities. Obstet Gynecol. 2007; 109(1):217-227.
3. Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn. 2011;31(1):7-15.
4. Fortuny A, Borrell A, Soler A, Casals E, Costa D, Carrio A, Puerto B, Seres A, Cararach J, Delgado R. Chorionic villus sampling by biopsy forceps. Results of 1580 procedures from a single centre. Prenat Diagn. 1995;15(6):541-50.
5. Crandall BF, Kulch P, Tabsh K. Risk assessment of amniocentesis between 11 and 15 weeks: comparison to later amniocentesis controls. Prenat Diagn. 1994;14(10):913-9.
6. Tabor A, Alfirevic Z. Update on procedure-related risks for prenatal diagnosis techniques. Fetal Diagn Ther. 2010;27(1):1-7.
7. Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, Wainscoat JS. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350(9076):485-7.
8. Benn P, Cuckle H, Pergament E. Non-invasive prenatal testing for aneuploidy: current status and future prospects. Ultrasound Obstet Gynecol. 2013;42(1):15-33.
9. Norton ME, Brar H, Weiss J, Karimi A, Laurent LC, Caughey AB, Rodriguez MH, Williams J 3rd, Mitchell ME, Adair CD, et al. Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol. 2012; 207(2):137 e131-138.
10. Jeon YJ, Zhou Y, Li Y, Guo Q, Chen J, Quan S, Zhang A, Zheng H, Zhu X, Lin J, et al. The feasibility study of non-invasive fetal trisomy 18 and 21 detection with semiconductor sequencing platform. PLoS One. 2014;9(10):e110240.
11. Wang E, Batey A, Struble C, Musci T, Song K, Oliphant A. Gestational age and maternal weight effects on fetal cell-free DNA in maternal plasma. Prenat Diagn. 2013;33(7):662-6.
12. Chan KC, Zhang J, Hui AB, Wong N, Lau TK, Leung TN, Lo KW, Huang DW, Lo YM. Size distributions of maternal and fetal DNA in maternal plasma. Clin Chem. 2004;50(1):88-92.
13. Lo YM, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet. 1999;64(1):218-24.
14. Smid M, Galbiati S, Vassallo A, Gambini D, Ferrari A, Viora E, Pagliano M, Restagno G, Ferrari M, Cremonesi L. No evidence of fetal DNA persistence in maternal plasma after pregnancy. Hum Genet. 2003;112(5-6):617-8.
15. Grati FR, Malvestiti F, Ferreira JC, Bajaj K, Gaetani E, Agrati C, Grimi B, Dulcetti F, Ruggeri AM, De Toffol S, et al. Fetoplacental mosaicism: potential implications for false-positive and false-negative noninvasive prenatal screening results. Genet Med. 2014;16(8):620-4.
16. McNamara CJ, Limone LA, Westover T, Miller RC. Maternal source of false-positive fetal sex chromosome aneuploidy in noninvasive prenatal testing. Obstet Gynecol. 2015;125(2):390-2.
17. Wang Y, Chen Y, Tian F, Zhang J, Song Z, Wu Y, Han X, Hu W, Ma D, Cram D, et al. Maternal mosaicism is a significant contributor to discordant sex chromosomal aneuploidies associated with noninvasive prenatal testing. Clin Chem. 2014;60(1):251-9.
18. Bianchi DW, Parker RL, Wentworth J, Madankumar R, Saffer C, Das AF, Craig JA, Chudova DI, Devers PL, Jones KW, et al. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med. 2014;370(9):799-808.
19. Sparks AB, Struble CA, Wang ET, Song K, Oliphant A. Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. Am J Obstet Gynecol. 2012; 206(4):319. e311-319.
20. Lau TK, Cheung SW, Lo PS, Pursley AN, Chan MK, Jiang F, Zhang H, Wang W, Jong LF, Yuen OK, et al. Non-invasive prenatal testing for fetal chromosomal abnormalities by low-coverage whole-genome sequencing of maternal plasma DNA: review of 1982 consecutive cases in a single center. Ultrasound Obstet Gynecol. 2014;43(3):254-64.
21. Ehrich M, Deciu C, Zwiefelhofer T, Tynan JA, Cagasan L, Tim R, Lu V, McCullough R, McCarthy E, Nygren AO, et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: A study in a clinical setting. Am J Obstet Gynecol. 2011;204(3):205. e201-211.
22. Ashoor G, Syngelaki A, Wagner M, Birdir C, Nicolaides KH. Chromosomeselective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. Am J Obstet Gynecol. 2012;206(4):322. e321-325.
23. Liao C, Yin AH, Peng CF, Fu F, Yang JX, Li R, Chen YY, Luo DH, Zhang YL, Ou YM, et al. Noninvasive prenatal diagnosis of common aneuploidies by semiconductor sequencing. Proc Natl Acad Sci U S A. 2014;111(20):7415-20.
24. Vrachnis N, Vlachadis N, Creatsas G. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med. 2014;371(6):578.
25. Yuan Y, Jiang F, Hua S, Du B, Hao Y, Ye L, Liu J, Feng K, Huang X, Yi X, et al. Feasibility study of semiconductor sequencing for noninvasive prenatal detection of fetal aneuploidy. Clin Chem. 2013;59(5):846-9.
26. Wang Y, Wen Z, Shen J, Cheng W, Li J, Qin X, Ma D, Shi Y. Comparison of the performance of Ion Torrent chips in noninvasive prenatal trisomy detection. J Hum Genet. 2014;59(7):393-6.
27. Barch MJKT, Spurbeck JL. The AGT cytogenetics laboratory manual. 3rd ed. New York: Lippincott-Raven; 1997.
28. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754-60.
29. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10(3):R25.
30. Li R, Yu C, Li Y, Lam TW, Yiu SM, Kristiansen K, Wang J. SOAP2: An improved ultrafast tool for short read alignment. Bioinformatics. 2009;25(15):1966-7.
31. Quail MA, Smith M, Coupland P, Otto TD, Harris SR, Connor TR, Bertoni A, Swerdlow HP, Gu Y. A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genomics. 2012;13:341.
32. Boland JF, Chung CC, Roberson D, Mitchell J, Zhang X, Im KM, He J, Chanock SJ, Yeager M, Dean M. The new sequencer on the block: comparison of Life Technology's Proton sequencer to an Illumina HiSeq for whole-exome sequencing. Hum Genet. 2013;132(10):1153-63.
33. Chen S, Li S, Xie W, Li X, Zhang C, Jiang H, Zheng J, Pan X, Zheng H, Liu JS, et al. Performance comparison between rapid sequencing platforms for ultra-low coverage sequencing strategy. PLoS One. 2014;9(3):e92192.
34. Henry GP, Britt DW, Evans MI. Screening advances and diagnostic choice: The problem of residual risk. Fetal Diagn Ther. 2008;23(4):308-15.
35. Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M, van den Boom D, Bombard AT, Deciu C, Grody WW, et al. DNA sequencing of maternal plasma to detect Down syndrome: An international clinical validation study. Genet Med. 2011;13(11):913-20.
36. Song K, Musci TJ, Caughey AB. Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population. J Matern Fetal Neonatal Med. 2013;26(12):1180-5.